Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

2.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. No abstract available.

PMID:
28482720
3.

Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.

Sorasio R, Bonferroni M, Grasso M, Strola G, Rapezzi D, Marenchino D, Di Marco C, Castellino C, Mattei D, Mordini N, Fiore F, Celeghini I, Borra A, Ghiglia A, Gallamini A.

Biol Blood Marrow Transplant. 2014 May;20(5):717-23. doi: 10.1016/j.bbmt.2014.02.002. Epub 2014 Feb 11.

4.

Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.

Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P, Omedè P, Pautasso M, Prato G, Strola G, Gioia D, Bonferroni M, Cametti G, Ferrero D, Freilone R, Gaidano G, Marinone C, Marmont F, Pollio B, Salvi F, Saglio G, Girotto M; Piedmont MDS Registry--Italy.

Eur J Haematol. 2011 Nov;87(5):409-18. doi: 10.1111/j.1600-0609.2011.01676.x. Epub 2011 Aug 11.

PMID:
21711395
5.

Scleroderma and hairy-cell leukemia.

Cavallero GB, Bonferroni M, Gallamini A, Grasso M, Carbone A.

Eur J Haematol. 1994 Mar;52(3):189-90. No abstract available.

PMID:
8168602
6.

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.

Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F.

Blood. 1991 Aug 15;78(4):1041-6.

7.

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.

Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Guarini A, Tos AG, di Celle PF, Cesano A, Matera L.

Blood. 1990 Oct 1;76(7):1349-54.

8.

[Pleural effusion in a case of non-Hodgkin's lymphoma: diagnostic use of molecular analysis].

Cavallero GB, Bonferroni M, di Celle PF, Gallamini A, Foà R.

Recenti Prog Med. 1990 Sep;81(9):568-70. Italian.

PMID:
2263751
9.

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin.

Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A, Lista P, Pegoraro L, Mandelli F, Forni G, et al.

Br J Haematol. 1990 May;75(1):34-40.

PMID:
2375921
10.

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alphadagger.

Bellone G, Fierro MT, Liao XS, Tos AG, Bonferroni M, Pegoraro L, Foa R.

Leuk Lymphoma. 1990;1(5-6):341-52. doi: 10.1080/10428199009169604.

PMID:
20394563
11.

Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells.

Lista P, Fierro MT, Liao XS, Bonferroni M, Brizzi MF, Porcu P, Pegoraro L, Foa R.

Eur J Haematol. 1989 May;42(5):425-30.

PMID:
2786477
12.

Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.

Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Liao XS, Cesano A, Matera L, Gillio Tos A, Tola E, et al.

Bone Marrow Transplant. 1989 Jan;4 Suppl 1:153-5. Review.

PMID:
2653494
13.

Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN).

Lauria F, Foà R, Raspadori D, Zinzani PL, Buzzi M, Fierro MT, Bonferroni M, Fanin R, Gallizia C, Michieli MG, et al.

Eur J Cancer Clin Oncol. 1988 Feb;24(2):195-200.

PMID:
3356206
14.

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.

Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R.

Leukemia. 1988 Jan;2(1):50-4.

PMID:
3257539
15.

Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia.

Foa R, Giovarelli M, Fierro MT, Bonferroni M, Forni G.

Nouv Rev Fr Hematol. 1988;30(5-6):339-41. Review.

PMID:
3065732
16.

Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.

Foa R, Fierro MT, Lusso P, Bonferroni M, Raspadori D, Buzzi M, Zinzani PL, Resegotti L, Lauria F.

Leukemia. 1987 Apr;1(4):377-9.

PMID:
3499543
17.

Supplemental Content

Loading ...
Support Center